Vivesto AB (publ)

Climate Impact & Sustainability Data (2019-05-01 to 2020-04-30, 2022)

75% of Oasmia’s employees at the end of the financial year 2019/20 had a university degree, of which more than a third had a Ph.D.
At the end of the financial year 2019/20, the Group had 63 employees, of whom 51% were women and 49% men.
The gender breakdown between managers at the company was 50% women and 50% men.

Long-term Goals:

Medium-term Goals:

Apealea® milestone payments and royalties
Docetaxel micellar Phase 1 Study Results
Realisation of cost control measures
M&A opportunities
Transition to Speciality Pharma Company
Greater focus on R&D and clinical trial GMP manufacturing as opposed to commercial manufacturing.

Short-term Goals:

COVID-19 pandemic significantly hampered and delayed the launch of Apealea in the Nordic region.
Legal issues related to patents registered in the name of Ardenia Investment Ltd.
Competitors with established products and market channels.
Uncertainty about appropriate pricing levels for Oasmia’s product candidates.
Dependence on collaborations with other companies for clinical trials, manufacturing, marketing, distribution and sale of products.

Implemented business continuity protocols and remote working policy.
Initiated recordation of assignment of patents.
Seeking partnerships with well-established companies and identifying alternatives to suppliers and manufacturers.
Cost control program designed to maximize resources and enable investment in areas with greatest return.
Focus on R&D and clinical trial GMP manufacturing as opposed to commercial manufacturing.

Frameworks Used: IFRS

Third-party Assurance: KPMG AB

Closed down environmentally hazardous operations in 2022 (approved by Uppsala Municipality Environmental Administration).

Strives to create a work environment that is conducive to health and well-being, with a low rate of sickness absence.
Conducts an annual salary review aimed at determining whether salary differences between women and men are directly or indirectly linked to gender and, if so, acts to eliminate these differences.

General market volatility
Slower than expected launch and sales of Apealea in Europe
Uncertainty regarding the launch activities of Apealea due to Elevar's decision to transfer rights to a third party
War in Ukraine and its impact on Russian operations and global markets.

Intensive work with Elevar to explore opportunities presented by the new situation regarding Apealea.
Working to find a partner for Apealea in China.
Write-down of balance sheet items amounting to MSEK 190 in the annual report due to uncertainty regarding Apealea.
Decided to wind down activities in Russia due to the war in Ukraine and international sanctions.
Continuous work to reduce the cost base.

External partners must be selected based on environmental and ethical criteria.
Vivesto has a well-defined policy and procedure for supplier controls, through which suppliers are assessed and monitored, including on environmental and ethical aspects.

Frameworks Used: IFRS

Third-party Assurance: KPMG AB